The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Published version of a preprint
Abstract
More than 90% of clear cell renal cell carcinomas (ccRCC) exhibit inactivation of the von Hippel–Lindau (pVHL) tumor suppressor, establishing it as the major underlying cause of this malignancy. pVHL inactivation results in stabilization of the hypoxia-inducible transcription factors, HIF1α and HIF2α, leading to expression of a genetic program essential for the initiation and progression of ccRCC. Herein, we describe the potent, selective, and orally active small-molecule inhibitor PT2385 as a specific antagonist of HIF2α that allosterically blocks its dimerization with the HIF1α/2α transcriptional dimerization partner ARNT/HIF1β. PT2385 inhibited the expression of HIF2α-dependent genes, including VEGF-A, PAI-1, and cyclin D1 in ccRCC cell lines and tumor xenografts. Treatment of tumor-bearing mice with PT2385 caused dramatic tumor regressions, validating HIF2α as a pivotal oncogenic driver in ccRCC. Notably, unlike other anticancer agents that inhibit VEGF receptor signaling, PT2385 exhibited no adverse effect on cardiovascular performance. Thus, PT2385 represents a novel class of therapeutics for the treatment of RCC with potent preclincal efficacy as well as improved tolerability relative to current agents that target the VEGF pathway. Cancer Res; 76(18); 5491–500. ©2016 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, compounds designated PT2385 and PT2977 were shown to selectively block dimerization of HIF-2α with HIF-1β (44)”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [44]
In the citing paper
“Belzutifan and its predecessor PT2385 bind to a hydrophobic cavity within the PAS-B domain of HIF-2α, allosterically preventing heterodimerization with HIF-1β and formation of a transcriptionally active complex [410].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [410]
In the citing paper
“Indeed, recent studies have shown that HIF-2α can be targeted by selective inhibitors and have indicated that these molecules effectively suppress cancer cell growth and tumor angiogenesis characteristics in ccRCC79–82.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [80]
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,961
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Cited by
Sorted by citations
Items 301–339 of 339
Systemic Therapy Options in VHL Disease
Jonasch, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-53858-2_10
The development of innovative therapeutic drugs targeting hypoxia responses
Yoshikawa, K., Hagimoto, H., & Nakamura, E. (2024) · Folia Pharmacologica Japonica · doi:10.1254/fpj.23090
Scovell, J. M., Balasubramanian, A., Lundy, S. D., & Bajic, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-90186-4.00080-8
Stereotactic Radiosurgery for Hemangioblastomas
Park, D. J., Yoo, K. H., Windisch, P. Y., Pollom, E. L., Meola, A., & Soltys, S. G. (2024) · Springer eBooks · doi:10.1007/978-3-031-67878-3_22
Trinh, V. T., Fischer, S., Zhang, L., Geisler, H., Pardo, B., Liefke, R., Abendroth, F., & Vázquez, O. (2025) · Angewandte Chemie · doi:10.1002/ange.202511183
Punia, R., & Goel, G. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01556
Development of a Novel HIF-2α PET Tracer for Noninvasive Tumor Hypoxia Imaging
Wang, Y.-L., Wang, C., Bai, P., Cui, J., Zhou, Y., Li, H., Wu, L., Wang, H., Bai, S., Ya, R., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c07799 · Cited by 1
Fengzhi, L. I., Aljahdali, I. A. M., Zhang, R., Nastiuk, K. L., Krolewski, J. J., & Ling, X. (2021) · Figshare · doi:10.6084/m9.figshare.15162096
Xie, J. M., Zhang, Y., Li, B., Xi, W., Wang, Y., Li, L., Liu, C., Shen, L., Han, B., Kong, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26690243
Arnaiz, E., Miar, A., Bridges, E., Prasad, N., Hatch, S. B., Ebner, D., Lawrie, C. H., & Harris, A. L. (2021) · Figshare · doi:10.6084/m9.figshare.15122301
Arnaiz, E., Miar, A., Bridges, E., Prasad, N., Hatch, S. B., Ebner, D., Lawrie, C. H., & Harris, A. (2021) · Figshare · doi:10.6084/m9.figshare.15122289
Xie, J., Zhang, Y., Li, B., Xi, W., Wang, Y., Li, L., Liu, C., Shen, L., Han, B., Kong, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26690240
Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small MoleculesPreprint
Fouad, M. A., Parry, C. S., Miller, S. A., Malhotra, S., Doyle, G. A. R., Shimabenga, E., Nurilloeva, M., Bondarenko, E., Andrianov, G. V., Childers, W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.02.697373
Identification of novel HIF2α inhibitors: a structure‐based virtual screening approach
Zhou, S., Yin, S., Yang, S., Wang, Y., & Feng, P. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2606435
Roennfeldt, A. E., Dinh, D. T., McPhee, T. R., Rose, R., Smith, K. M., Jayapal, M., Allen, T. P., Robker, R. L., Bersten, D. C., Peet, D. J., et al. (2026) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2026.112754
Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small MoleculesPreprint
Fouad, M. A., Parry, C. S., Miller, S. A., Malhotra, S., Doyle, G. A. R., Shimabenga, E., Nurilloeva, M., Bondarenko, E. A., Andrianov, G. V., Childers, W. E., et al. (2026) · eLife · doi:10.7554/elife.110305.1
Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small MoleculesPreprint
Fouad, M. A., Parry, C. S., Miller, S. A., Malhotra, S., Doyle, G. A. R., Shimabenga, E., Nurilloeva, M., Bondarenko, E. A., Andrianov, G. V., Childers, W. E., et al. (2026) · eLife · doi:10.7554/elife.110305
Le rôle de l'érythroferrone dans la régulation du métabolisme du fer
Sardo, U. (2020) · theses.fr (ABES) · doi:10.70675/d03e67aczc44bz4af9z8fa1zef080668f44f
Role of hypoxia and metabolism in the maturation of hemodialysis arteriovenous fistulas
Sadaghianloo, N. (2018) · theses.fr (ABES) · doi:10.70675/dd46cd88z0b28z473fz9684zb469ec41bcf3
Rôle de l'hypoxie dans l'immunothérapie des ostéosarcomes pédiatriques ciblant le GD2
Pierrevelcin, M. (2021) · theses.fr (ABES) · doi:10.70675/9d2c6f5dzb23ez4823z9c0fze8ea3c9c8bc7
Rôle et ciblage de HIF-2a dans les gliomes de haut-grade pédiatrique de la ligne médiane
Fuchs, Q. (2022) · theses.fr (ABES) · doi:10.70675/be0bde8bzaab7z4b1fz8704zbcdc0c236054
Métastases cérébrales et hypoxie : approches pré-cliniques in vitro et in vivo en imagerie TEP/IRM
Fantin, J. (2023) · theses.fr (ABES) · doi:10.70675/17c3d7d3zde37z4e93z9446zc690e62f8a7a
Hétérogénéité et plasticité de l’intégrine α5 dans les cellules souches de glioblastome
Messé, M. (2023) · theses.fr (ABES) · doi:10.70675/5bee424dz19e3z4870zb9b1z927eaa272304
shakeel, H. (2026) · Research Square · doi:10.21203/rs.3.rs-9336311/v1
Li, W., Xu, Q., Song, J., Song, W., Fei, M., Zhang, K., & Yan, Z. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168311
Fu, J., He, Y., Lu, J., Wei, H., Sun, W., Geng, J., Liu, K., Liu, J. J., Liu, Z., Wang, K., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00152
Self-citationJiménez, C., Waguespack, S. G., Kaplan, J., Habra, M. A., & Varghese, J. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag324
Fu, P., Shuai, G., Wen, D., Wang, Y., Yu, S., Xie, Y., Xue, P., Luo, H., Liang, Z., Zou, J., et al. (2026) · World Journal of Urology · doi:10.1007/s00345-026-06709-2 · Cited by 1
Luo, C., Li, T., Tak, J., DeBerge, M., Tsai, K., & Eltzschig, H. K. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01339-y
Lee, C., Byeon, Y., Kim, K., Lee, W., Hwang, K., Dho, Y., Sung, K. S., Roh, T. H., Chong, K., Park, K., et al. (2026) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2026.0009
BindingDB (2020) · UC San Diego · doi:10.7270/q2h997rj
BindingDB Entry 50019394: Discovery of Cycloalkyl[
BindingDB (2024) · UC San Diego · doi:10.7270/q2k3601n
BindingDB Entry 50006858: 3-[(1
BindingDB (2021) · UC San Diego · doi:10.7270/q2gx4ftx
Metadata
- Authors
- Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., Grina, J. A., Halfmann, M. M., Maddie, M. A., Olive, S. R., Schlachter, S. T., Tan, H., Wang, B., Wang, K., Xie, S., Xu, R., Yang, H., & Josey, J. A.
- Affiliations
- Peloton Therapeutics, Inc., Dallas, Texas.
- Corresponding author
- Wallace, Eli M.
- ORCID
- Venue
- Cancer Research
- Published
- 2016-09-15
- Volume
- 76
- Issue
- 18
- Pages
- 5491-5500
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2514212469
- Cited by
- 336
- References
- 40
- Citations by year
- 2026: 27 · 2025: 34 · 2024: 38 · 2023: 36 · 2022: 25 · 2021: 37 · 2020: 41 · 2019: 38 · 2018: 30 · 2017: 22 · 2016: 7
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-2α, PT2385, clear cell renal cell carcinoma, small molecule inhibitors, hypoxia-inducible factor, VEGF-A, plasminogen activator inhibitor-1, cyclin D1, tumor xenografts, oral anticancer therapy, cardiovascular safety
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Antineoplastic Agents, Calorimetry, Carcinoma, Renal Cell, Humans, Immunohistochemistry, Kidney Neoplasms, Polymerase Chain Reaction, Mice, SCID, Crystallography, X-Ray, Xenograft Model Antitumor Assays, Cell Line, Tumor, Immunoprecipitation, Mice, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
